

November 2011

**ANNUAL DECLARATION OF INTERESTS
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE
INVITED REVIEWERS FOR 2011 REPORT
1 January 2011 – 31 December 2011**

GOLD participants disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GOLD member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GOLD member or family members (spouse/dependent children <18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GOLD Committee member (or the Department/Institution on behalf of a GOLD member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$10,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each scientist invited to serve as a reviewer of the 2011 report is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Chronic Obstructive Lung Disease (GOLD)” on the website at: <<http://www.goldcopd.org>>.

SUMMARY FOR YEAR 2011:

Joan-Albert Barbera, Barcelona, Spain: *Personal Benefits* <\$10,000: Bayer, Actelion. *Shares:* none. *Non-Personal Interests:* none.

A. Sonia Buist, Portland OR, US: *Personal Benefits* <\$10,000: Merck Sharp & Dohme, Forest Laboratories. *Shares:* none. *Non-Personal Interests:* none.

Peter Calverley, Liverpool UK: *Personal Benefits* <\$10,000: GlaxoSmithKline, Nycomed. *Personal Benefits* >\$10,000: AstraZeneca, Boehringer Ingelheim, Novartis. *Shares:* none. *Non-Personal Interests* <\$10,000: GlaxoSmithKline.

Bart Celli, Boston MA, US: *Personal Benefits* <\$10,000: AstraZeneca, Almirall, Boehringer Ingelheim. *Personal Benefits* >\$10,000: GlaxoSmithKline. *Shares:* none. *Non-Personal Interests:* none.

M.W. Elliott, Leeds, UK: *Personal Benefits* <\$10,000: Curative Medical. *Shares:* none. *Non-Personal Interests* <\$10,000: Resmed.

Masakazu Ichinose, Wakayama, Japan: *Personal Benefits* <\$10,000: Abbott Japan Co, Novartis Pharma KK. *Personal Benefits* >\$10,000: AstraZeneca, GlaxoSmithKline, Nippon Boehringer

Ingelheim. *Shares*: none. *Non-Personal Interests >\$10,000*: Abbott Japan Co, AstraZeneca, GlaxoSmithKline, Nippon Boehringer Ingelheim, Novartis Pharma KK.

Christine Jenkins, NSW Australia: *Personal Benefits <\$10,000*: GlaxoSmithKline, Novartis. *Personal Benefits >\$10,000*: AstraZeneca. *Shares*: none. *Non-Personal Interests >\$10,000*: AstraZeneca, GlaxoSmithKline.

H.A.M. Kerstjens, Groningen, the Netherlands: *Personal Benefits*: none. *Shares*: none. *Non-Personal Interests <\$10,000*: Boehringer Ingelheim, Novartis, Nycomed, Pfizer.

Peter Lange, Copenhagen, Denmark: *Personal Benefits <\$10,000*: AstraZeneca, Boehringer-Ingelheim/Pfizer, GlaxoSmithKline, Nycomed. *Personal Benefits >\$10,000*: Novartis, Pfizer. *Shares*: none. *Non-Personal Interests >\$10,000*: GlaxoSmithKline.

Maria Victorian Lopez Varela, Montevideo, Uruguay: *Personal Benefits <\$10,000*: AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline. *Shares*: none. *Non-Personal Interests*: none.

Maria Montes de Oca, Caracas, Venezuela: *Personal Benefits <\$10,000*: AstraZeneca, Boehringer Ingelheim. *Shares*: none. *Non-Personal Interests*: none.

Dennis Niewoehner, Minneapolis MN, US: *Personal Benefits <\$10,000*: Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, Novartis. *Shares*: none. *Non-Personal Interests*: none.

David Price, Aberdeen, Scotland: *Personal Benefits <\$10,000*: Boehringer Ingelheim/Pfizer, GlaxoSmithKline, Mundipharma, Novartis. *Personal Benefits >\$10,000*: Boehringer Ingelheim, Merck Sharp & Dohme. *Shares*: none. *Non-Personal Interests >\$10,000*: Mundipharma, Novartis, Teva.

Nicolas Roche, Paris, France: *Personal Benefits <\$10,000*: Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MEDA, MundiPharma, Novartis, Nycomed, TEVA. *Shares*: none. *Non-Personal Interests <\$10,000*: Novartis, Nycomed. *Non-Personal Interests >\$10,000*: Boehringer Ingelheim.

Sanjay Sethi: *Personal Benefits <\$10,000*: AstraZeneca, Cornerstone, Forest Laboratories, GlaxoSmithKline, MerckSharpDohme, Novartis, Pearl Therapeutics, Pulmatrix. *Personal Benefits >\$10,000*: Bayer, Boehringer Ingelheim. *Shares*: none. *Non-Personal Interests >\$10,000*: AstraZeneca, Medical Acoustics, Pulmatrix.

All members confirmed no relation to, or income from, the tobacco industry.